PANTHER-IPF
PREDNISONE, AZATHIOPRINE,
AND N-ACETYLCYSTEINE:
A STUDY THAT EVALUATES RESPONSE IN
IDIOPATHIC PULMONARY FIBROSIS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Compiled by:
The PANTHER-IPF Protocol Committee
Version Date: May 19, 2009
Amendment 1 Date: May 28, 2010
Amendment 2 Date: December 6, 2011

Distributed by:
The IPFnet Coordinating Center
Duke Clinical Research Institute
Duke University
PO Box 17969
Durham, NC 27715
### Protocol Summary

<table>
<thead>
<tr>
<th><strong>PRODUCT</strong></th>
<th>N-acetylcysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLINICALTRIALS.GOV NUMBER</strong></td>
<td>NCT00650091</td>
</tr>
<tr>
<td><strong>PROTOCOL TITLE</strong></td>
<td>Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis (PANTHER-IPF)</td>
</tr>
<tr>
<td><strong>DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION</strong></td>
<td>Confirmed idiopathic pulmonary fibrosis, diagnosed within 48 months of enrollment; forced vital capacity ≥ 50% predicted; hemoglobin adjusted diffusing capacity of the lung ≥ 30% predicted</td>
</tr>
<tr>
<td><strong>STUDY OBJECTIVES</strong></td>
<td>To assess the safety and efficacy of N-acetylcysteine in subjects with newly diagnosed idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td><strong>STUDY DESIGN</strong></td>
<td>Multi-center, randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td><strong>TREATMENT REGIMENS</strong></td>
<td>1) N-acetylcysteine (600 mg TID), or 2) placebo</td>
</tr>
<tr>
<td><strong>ROUTE OF ADMINISTRATION</strong></td>
<td>Oral</td>
</tr>
<tr>
<td><strong>TIME BETWEEN FIRST AND LAST DOSES OF ACTIVE STUDY AGENT</strong></td>
<td>Maximum of 60 weeks</td>
</tr>
<tr>
<td><strong>NUMBER OF SUBJECTS</strong></td>
<td>Approximately 130 NAC, 130 placebo (1:1)</td>
</tr>
<tr>
<td><strong>NUMBER OF CLINICAL CENTERS</strong></td>
<td>Approximately 26 US sites</td>
</tr>
<tr>
<td><strong>PRIMARY ENDPOINT</strong></td>
<td>Change in longitudinal forced vital capacity measurements over 60 weeks</td>
</tr>
<tr>
<td><strong>INTERIM ANALYSIS</strong></td>
<td>Completed October 2011</td>
</tr>
</tbody>
</table>
Study Sponsor: National Heart Lung and Blood Institute

Acting Steering Group Chair: Marvin I. Schwarz, MD
University of Colorado - Denver

Project Officer: Gail Weinmann, MD
National Heart Lung and Blood Institute
Bethesda, MD

Protocol Committee Cochairs:

Ganesh Raghu, MD
University of Washington

Fernando J. Martinez, MD
University of Michigan

Data Coordinating Center:

Duke Clinical Research Institute
Duke University
Table of Contents

List of Tables ........................................................................................................................................ 7
List of Figures ....................................................................................................................................... 7
List of Abbreviations .......................................................................................................................... 8

1. Summary ............................................................................................................................................. 12

2. Hypotheses and Specific Aims ...................................................................................................... 13
   2.1. Null Hypothesis ....................................................................................................................... 13
   2.2. Specific Aim 1 .......................................................................................................................... 13
   2.3. Specific Aim 2 .......................................................................................................................... 13
   2.4. Prespecified Subgroups of Interest ............................................................................................14

3. Background and Significance .................................................................................................... 15
   3.1. Idiopathic Pulmonary Fibrosis is the Most Common Interstitial Lung Disease ..................... 15
   3.2. Rationale for Placebo Control .................................................................................................... 15
   3.3. Rationale for N-acetylcysteine .................................................................................................. 16
   3.4. Rationale for N-acetylcysteine as a Stand-alone Therapy ...................................................... 17
   3.5. Rationale for the Study Design and Primary Endpoint ............................................................ 18
   3.6. Rationale for Blinding of Treatments ....................................................................................... 19

4. Methods ............................................................................................................................................. 21
   4.1. Inclusion Criteria ....................................................................................................................... 21
   4.1.1. Subjects Shown to Have Usual Interstitial Pneumonia Pattern on Surgical Lung Biopsy ...... 21
   4.1.2. Subjects Who Have Not Undergone a Surgical Lung Biopsy .............................................. 21
   4.2. Diagnosis of IPF ....................................................................................................................... 21
   4.3. Exclusion Criteria ...................................................................................................................... 26
   4.4. Study Design and Study Visit .................................................................................................... 27
   4.4.1. Study Design Summary ......................................................................................................... 27
   4.4.2. Study Visits ............................................................................................................................ 28
   4.4.2.1. Screening .......................................................................................................................... 28
   4.4.2.2. Enrollment ......................................................................................................................... 29
   4.4.2.3. Week 15 ............................................................................................................................. 30
   4.4.2.4. Week 30 ............................................................................................................................. 31
   4.4.2.5. Week 45 ............................................................................................................................. 31
   4.4.2.6. Week 60 (Early Withdrawal or Final Treatment Visit) ..................................................... 32
   4.4.2.7. Final Site Visit – FVC drop confirmation .......................................................................... 33
   4.4.2.8. Final Visit – Telephone Follow-up .................................................................................... 33
   4.4.2.9. Phone Contact Between Visits ........................................................................................... 33
   4.5. Dose Justification ....................................................................................................................... 35
   4.5.1. Rationale for N-acetylcysteine Dosing ................................................................................ 35
   4.5.1.1. Dosing of N-acetylcysteine/placebo .................................................................................. 35
   4.5.1.2. Reasons to Discontinue N-acetylcysteine/placebo .............................................................. 35
   4.5.2. Dosage Algorithms .............................................................................................................. 37
   4.6. Contraindications, Precautions, and Side Effects of Study Medications ............................... 39
   4.6.1. Contraindication ................................................................................................................... 39
   4.6.2. Precautions ............................................................................................................................ 39
   4.6.3. Side Effects ........................................................................................................................... 39
   4.7. Recruitment Procedures ............................................................................................................ 40
   4.8. Study Procedures ....................................................................................................................... 41
   4.8.1. Biological Specimen Management ........................................................................................ 41
   4.8.1.1. Biological Specimen Sample Management .................................................................. 41
   4.9. Concomitant Medications ....................................................................................................... 42
   4.10. Laboratory Testing .................................................................................................................. 42
   4.11. Blinding of Study Drugs ......................................................................................................... 43
5. Study Endpoints........................................................................................................... 44
  5.1. Primary Study Endpoint........................................................................................... 44
  5.2. Secondary Study Endpoints ................................................................................... 44
    5.2.1. Time to Disease-progression ............................................................................ 44
    5.2.2. Acute Exacerbations ...................................................................................... 44
    5.2.3. Respiratory Infections .................................................................................... 47
    5.2.4. Maintained FVC Response ............................................................................. 48

6. Safety Evaluations and Procedures............................................................................. 49
  6.1. Adverse Events ....................................................................................................... 49
    6.1.1. Definitions ........................................................................................................ 49
    6.1.2. Adverse Event (AE) Reporting ....................................................................... 50
      6.1.2.1. Serious Adverse Events (SAE) Reporting .................................................. 50
      6.1.2.2. Regulatory Reporting ................................................................................. 51
  6.2. Clinical Medical Monitoring .................................................................................. 52
  6.3. Unblinding Procedures .......................................................................................... 52

7. Study Drug Procedures ................................................................................................. 53

8. Data Management.......................................................................................................... 54
  8.1. Hardware and Software Configuration .................................................................... 54
    8.1.1. Hardware and Database Software ................................................................. 54
    8.1.2. Statistical Software ......................................................................................... 54
    8.1.3. Access Control and Confidentiality Procedures ............................................. 54
    8.1.4. Security ........................................................................................................... 54
    8.1.5. Back-up Procedures ....................................................................................... 55
    8.1.6. Virus Protection .............................................................................................. 55
  8.2. Sources of Data ....................................................................................................... 55
    8.2.1. Design and Development .............................................................................. 55
    8.2.2. Data Collection Forms ................................................................................... 55
    8.2.3. Data Acquisition and Entry .......................................................................... 56
    8.2.4. Data Center Responsibilities ......................................................................... 56
    8.2.5. Data Editing .................................................................................................. 56
    8.2.6. Training ......................................................................................................... 56

9. Study Design and Data Analysis.................................................................................. 57
  9.1. General Analytic Considerations ........................................................................... 57
  9.2. Randomization, Blinding, and Reporting of Results ............................................. 57
  9.3. Stratification .......................................................................................................... 58
  9.4. Specification of the Primary Analyses ................................................................... 58
  9.5. Analysis of Longitudinal Endpoints ..................................................................... 58
  9.7. Power Analysis .................................................................................................... 60
    9.7.1. Primary Analyses ........................................................................................... 60
    9.7.2. Power Analysis for Secondary Endpoints .................................................... 61

10. Study Administration ................................................................................................ 62
   10.1. Cooperative Agreement Mechanism ..................................................................... 62
   10.2. IPFnet Steering Group ....................................................................................... 64
   10.3. Data and Safety Monitoring Board ..................................................................... 64
   10.4. Recommendations on Interim Monitoring of Efficacy, Safety, and Futility ........ 64

11. Investigator and Sponsor Obligations ...................................................................... 66
   11.1. Monitoring ........................................................................................................ 66
   11.2. Cost and Payment .............................................................................................. 66
   11.3. Confidentiality and Health Insurance Portability and Accountability Act Considerations .............................................................................................................. 66
   11.4. Informed Consent Procedures .......................................................................... 67
   11.5. Institutional Review Boards .............................................................................. 67
**List of Tables**

- Table 1: Operating Characteristics of Local HRCT Review for Diagnosis of UIP (24)
- Table 2: Combining HRCT and Pathology Interpretations to Determine if IPF is Present (25)
- Table 3: Schedule of Assessments (34)
- Table 4: Side Effects of NAC (40)
- Table 5: Final Diagnoses in Evaluation of Suspected Acute Exacerbations (46)
- Table 6: Hypothetical Values of Mean FVC (L) Change from Baseline (61)
- Table 7: Detectable Differences in Treatment Means for Selected Endpoint Measurements (61)

**List of Figures**

- Figure 1: Changes in Forced Vital Capacity from Baseline in Prior IPF Clinical Trials (19)
- Figure 2: Diagnosis of Idiopathic Pulmonary Fibrosis in the IPFnet (22)
- Figure 3: Pathology Flow Chart: Surgical Lung Biopsy Diagnosis (23)
- Figure 4: Acute Exacerbation Flow Chart (47)
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6MWT</td>
<td>6-minute walk test</td>
</tr>
<tr>
<td>A-aPO₂</td>
<td>alveolar-arterial PO₂ difference</td>
</tr>
<tr>
<td>ABG</td>
<td>arterial blood gas</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>AEx</td>
<td>acute exacerbation</td>
</tr>
<tr>
<td>A/G</td>
<td>albumin/globulin</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>ATS</td>
<td>American Thoracic Society</td>
</tr>
<tr>
<td>AZA</td>
<td>azathioprine</td>
</tr>
<tr>
<td>BAL</td>
<td>bronchoalveolar lavage</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>cGMP</td>
<td>Current Good Manufacturing Practice</td>
</tr>
<tr>
<td>CPI</td>
<td>Composite Physiologic Index</td>
</tr>
<tr>
<td>CPK</td>
<td>creatine phosphokinase</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>DCC</td>
<td>Data Coordinating Center</td>
</tr>
<tr>
<td>DCRI</td>
<td>Duke Clinical Research Institute</td>
</tr>
<tr>
<td><strong>Abbreviation</strong></td>
<td><strong>Definition</strong></td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>DLCO</td>
<td>diffusing capacity of the lung for carbon monoxide</td>
</tr>
<tr>
<td>DLCO%pred</td>
<td>diffusing capacity of the lung for carbon monoxide percent predicted</td>
</tr>
<tr>
<td>DSMB</td>
<td>data and safety monitoring board</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>ERS</td>
<td>European Respiratory Society</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration (U.S.)</td>
</tr>
<tr>
<td>FEV₁</td>
<td>forced expiratory volume in 1 second</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>FVC</td>
<td>forced vital capacity</td>
</tr>
<tr>
<td>FVC%pred</td>
<td>forced vital capacity percent predicted</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma glutamyl transferase</td>
</tr>
<tr>
<td>GSH</td>
<td>glutathione</td>
</tr>
<tr>
<td>HAD</td>
<td>Hospital Anxiety and Depression</td>
</tr>
<tr>
<td>HHS</td>
<td>Health &amp; Human Services (U.S. Dept. of)</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HRCT</td>
<td>high-resolution computed tomography</td>
</tr>
<tr>
<td>IBW</td>
<td>ideal body weight</td>
</tr>
<tr>
<td>ICE CAP</td>
<td>Investigating Choice Experiments for Preferences of Older People Capability Instrument</td>
</tr>
<tr>
<td>ILD</td>
<td>interstitial lung disease</td>
</tr>
<tr>
<td>IPF</td>
<td>idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>IPFnet</td>
<td>Idiopathic Pulmonary Fibrosis Clinical Research Network</td>
</tr>
<tr>
<td>IRB</td>
<td>institutional review board</td>
</tr>
<tr>
<td>ITT</td>
<td>intent to treat</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>IVRS</td>
<td>interactive voice response system</td>
</tr>
<tr>
<td>LDH</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>LFT</td>
<td>liver function test</td>
</tr>
<tr>
<td>LOCF</td>
<td>last observation carried forward</td>
</tr>
<tr>
<td>LSD</td>
<td>Least Significant Difference</td>
</tr>
<tr>
<td>MAR</td>
<td>missing at random</td>
</tr>
<tr>
<td>MCAR</td>
<td>missing completely at random</td>
</tr>
<tr>
<td>MMRM</td>
<td>mixed model repeated measures</td>
</tr>
<tr>
<td>MOOP</td>
<td>manual of operating procedures</td>
</tr>
<tr>
<td>NAC</td>
<td>N-acetylcysteine</td>
</tr>
<tr>
<td>NHLBI</td>
<td>National Heart Lung and Blood Institute (U.S.)</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health (U.S.)</td>
</tr>
<tr>
<td>NSIP</td>
<td>nonspecific interstitial pneumonia</td>
</tr>
<tr>
<td>PaO₂</td>
<td>partial pressure of arterial oxygen</td>
</tr>
<tr>
<td>PCP</td>
<td>primary care provider</td>
</tr>
<tr>
<td>PFT</td>
<td>pulmonary function test</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>PHS</td>
<td>Public Health Service (U.S.)</td>
</tr>
<tr>
<td>PI</td>
<td>principal investigator</td>
</tr>
<tr>
<td>PL</td>
<td>placebo</td>
</tr>
<tr>
<td>PLT</td>
<td>platelet</td>
</tr>
<tr>
<td>PRED</td>
<td>prednisone</td>
</tr>
<tr>
<td>QOL</td>
<td>quality of life</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>statistical analysis plan</td>
</tr>
<tr>
<td>SGRQ</td>
<td>St. George’s Respiratory Questionnaire</td>
</tr>
<tr>
<td>SpO₂</td>
<td>oxygen saturation by pulse oximetry</td>
</tr>
<tr>
<td>TPMT</td>
<td>thiopurine methyl transferase</td>
</tr>
<tr>
<td>UCSD SOBQ</td>
<td>University of California at San Diego Shortness of Breath Questionnaire</td>
</tr>
<tr>
<td>UIP</td>
<td>usual interstitial pneumonia</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>USP</td>
<td>United States Pharmacopoeia</td>
</tr>
<tr>
<td>VC</td>
<td>vital capacity</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
</tbody>
</table>
1. Summary

There are currently no drug therapies that have proven to be effective in the treatment of idiopathic pulmonary fibrosis (IPF). Previous clinical drug trials have been difficult to interpret due to lack of true placebo (PL) controls or other methodological concerns. Clinical efficacy of immunosuppressive therapies and agents that reduce oxidative stress remains controversial. The IPF Clinical Research Network (IPFnet) is conducting a randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of N-acetylcysteine (NAC) as monotherapy in subjects with mild or moderate IPF.

The study initially employed a 3-arm design with 1:1:1 randomization to NAC, azathioprine (AZA)-prednisone (PRED)-NAC, and PL, with each subject to be treated up to a maximum of 60 weeks, followed by a tapering of PRED/PL and a 4-week period for safety evaluation. Approximately 390 subjects who have mild to moderate IPF (defined as forced vital capacity percent predicted \([\text{FVC}\%\text{pred}] \geq 50\%\) and diffusing capacity of the lung for carbon monoxide percent predicted \([\text{DLCO}\%\text{pred}] \geq 30\%\) diagnosed within the past 48 months were to be enrolled.

At the pre-specified interim analysis, the DSMB recommended termination of the prednisone-azathioprine-NAC arm of the study. No additional patients will be randomized to that arm. However, the NAC and placebo arms remain open for enrollment, and we will enroll approximately 130 subjects in each arm (inclusive of the subjects enrolled at the time of the interim analysis.) Follow up for subjects enrolled into the two arms will continue for 60 weeks.

The primary endpoint is the change in longitudinal measurements of FVC over the study period. The primary goal of this study to establish an evidence-based standard of care and clarify myths from facts for pharmacotherapy of IPF has been met, in part, by demonstrating that the widely used triple therapy was harmful to patients with IPF (NHLBI press release, Oct 21, 2011). To determine the potential therapeutic benefits of NAC alone, the study will continue to enroll patients as a two-arm, double-blind, placebo-controlled study from this point on (NAC vs. placebo) as recommended by the DSMB following the pre-specified interim analysis.
2. Hypotheses and Specific Aims

2.1. Null Hypothesis

Treatment with NAC will provide the same efficacy as PL, as measured by longitudinal changes in FVC.

2.2. Specific Aim 1

This study is designed to assess the safety and efficacy of NAC in subjects with newly diagnosed IPF.

2.3. Specific Aim 2

Secondary goals of this study are to assess differences between treatment groups for the following:

1. Mortality
2. Time to death
3. Frequency of acute exacerbations (AExs)
4. Frequency of maintained FVC response
5. Time-to-disease progression
6. Change in DLco
7. Change in Composite Physiologic Index (CPI)
8. Change in resting alveolar-arterial oxygen gradient
9. Change in 6-minute walk test (6MWT) distance
10. Change in 6MWT oxygen saturation area under the curve
11. Change in 6MWT distance to desaturation < 80%
12. Change in 6MWT minutes walked
13. Changes in health status as measured by the SF-36, EuroQol, and St. George’s Respiratory Questionnaire (SGRQ)
14. Changes in dyspnea as measured by the University of California at San Diego Shortness of Breath Questionnaire (UCSD SOBQ)
15. Frequency and types of adverse events (AEs)
16. Frequency and types of respiratory complications, both infectious and noninfectious
17. Frequency of hospitalizations, both all-cause and respiratory-related
2.4. Prespecified Subgroups of Interest

Treatment effects will be estimated and compared within key subgroups:

- Higher enrollment FVC\textsuperscript{1,2}
- Typical vs. atypical high-resolution computed tomography (HRCT) reading at baseline\textsuperscript{3}
- Recent vs. more remote diagnosis (time from initial diagnosis of IPF ≤ 1 year and > 1 year)
- Lower CPI score at enrollment\textsuperscript{4}
- Medical therapy for gastroesophageal reflux\textsuperscript{5}
- Ethnic background
- Sex
- Smoking history (current or ex-smoker vs. never smoker), given potential impact on oxidant status\textsuperscript{6}
- Presence of emphysema > 25% on HRCT
3. Background and Significance

3.1. Idiopathic Pulmonary Fibrosis is the Most Common Interstitial Lung Disease

IPF is the most common interstitial lung disease (ILD) of unknown etiology. The current incidence and prevalence of IPF in the United States are not known. A 1994 study of a population-based registry of subjects in Bernalillo County, New Mexico, USA, estimated an incidence of 10.7 cases per 100,000 per year for males and 7.4 cases per 100,000 per year for females; the prevalence of IPF was estimated at 20 per 100,000 for males and 13 per 100,000 for females. Extrapolating from a large healthcare claims database, a more recent review estimated the prevalence of IPF in the United States at 42.7 per 100,000 (incidence estimated at 16.3 per 100,000 per year). Recent epidemiological studies indicate increasing mortality rates from IPF in the United States and other industrialized nations.

Approximately two-thirds of subjects with IPF are over the age of 60 at the time of presentation, and the incidence increases with age. IPF has no distinct geographical distribution, and predilection by race or ethnicity has not been identified. Individual subjects may remain relatively stable for prolonged periods, experience very slow declines in lung function with progression of radiographic abnormalities for a period of months to years, or experience more rapid declines and subsequent death. Only 20% to 30% of IPF patients survive for 5 years following diagnosis.

There is currently no proven, effective pharmacological treatment for IPF. Anti-inflammatory and immunosuppressive agents have been the traditional approach to the management of patients with IPF. Based on the results of the interim analysis of the PANTHER-IPF trial, this ‘traditional approach’ will be aborted. However, it remains unknown if NAC alone will prove beneficial in IPF patients. The primary goal of the modified study is to establish an evidence-based standard of care and clarify the role of this specific antioxidant pharmacotherapy for IPF.

3.2. Rationale for Placebo Control

IPF is a disorder for which there is no proven efficacious therapy. A major objective of this trial is to test, to the greatest degree possible, a proposed standard of care for patients with IPF. The current traditional therapy
employs immunosuppressive and corticosteroid drugs. Interim review of the original PANTHER-IPF study has documented increased adverse events and lack of efficacy for AZA-PRED-NAC compared to placebo suggesting that this therapeutic approach should not be employed. Whether this applies to NAC alone, which has been advocated by international societies, has not been proven in well-designed, well-powered clinical trials. The recommendations made in the recently published evidence guidelines for NAC monotherapy was weak based on low quality. Thus, this continued clinical trial randomizing patients to receive NAC or placebo is pivotal and will answer the important question of the potential therapeutic benefits of NAC monotherapy with grade A evidence. In this prospective, randomized clinical trial, the inclusion of a PL arm is therefore vital to adequately test the benefits of NAC in well-characterized subjects with IPF.

If NAC has no true efficacy, then its role as standard of care will be refuted. If a benefit compared with PL is confirmed, it will establish a benchmark against which future novel therapies for IPF will be safely compared. As there is no currently accepted therapy for IPF, there is an increasing body of published literature supporting the concept of no treatment as the “best care” option for IPF.

Post hoc analyses of PL-controlled trials suggest that subjects with milder disease may be more amenable to therapy. It is notable that a recent international, prospective, randomized trial of interferon-gamma for IPF also included a PL arm; the study was terminated early by the data and safety monitoring board (DSMB) due to lack of treatment effect. This underscores the belief that a proven effective therapy for IPF does not currently exist and that true placebo-controlled trials remain the gold standard. Similarly, recently completed trials of etanercept, everolimus, bosentan and BIPF 1120 in IPF have included PL-treated arms. In three of these trials, the treated subjects showed little, if any, objective improvement. Based on this evidence and the current status of IPF therapy and therapeutic trials, we believe that clinicians and subjects will continue to enroll in a PL-controlled study.

3.3. Rationale for N-acetylcysteine

NAC is a derivative of the amino acid L-cysteine. NAC has been shown to augment levels of the naturally occurring antioxidant glutathione (GSH) both in vitro and in vivo. GSH is present in all eukaryotic cells and may play an important role in protecting alveolar epithelial cells against oxidant injury. The concentration of GSH in the bronchoalveolar lavage (BAL) fluid in patients
with IPF is markedly diminished compared with normal subjects. This GSH deficiency may be corrected by exogenous administration of NAC.\textsuperscript{21,22}

There is evidence of enhanced production of oxidants in an IPF lung. Both inflammatory cells and myofibroblasts derived from patients with IPF generate increased amounts of extracellular oxidants, including hydrogen peroxide.\textsuperscript{23,24} Secretion of hydrogen peroxide by activated myofibroblasts may induce the death of adjacent lung epithelial cells by paracrine mechanisms.\textsuperscript{24} Additionally, generation of oxidants by myofibroblasts induces oxidative crosslinking of extracellular matrix proteins,\textsuperscript{25} a potential mechanism for aberrant matrix remodeling. Thus, an oxidant-antioxidant imbalance exists in the lungs of IPF patients.\textsuperscript{26} NAC may confer protection against this imbalance by augmenting GSH levels in addition to its more direct free-radical scavenging activity.

Intravenous (IV) NAC therapy has been shown to increase total BAL GSH in 8 IPF subjects.\textsuperscript{27} Oral NAC (600 mg 3 times per day) has been shown to decrease markers of oxidant injury and improve both total and reduced GSH levels in the epithelial lining fluid of subjects with IPF in a small, uncontrolled study;\textsuperscript{22} pulmonary function improved modestly with therapy. A similar study in 18 IPF subjects confirmed increased intracellular GSH concentration after 12 weeks of NAC (600 mg 3 times per day);\textsuperscript{22,28} no clinical correlates were reported. Inhaled NAC was suggested to improve pulmonary function in an open label study.\textsuperscript{29}

3.5. Rationale for N-acetylcysteine as a Stand-alone Therapy

Results of a double-blind, multi-center European clinical trial of 150 IPF subjects testing combinations of AZA-PRED vs. AZA-PRED-NAC have been reported.\textsuperscript{30} NAC added to AZA-PRED (“conventional therapy”) had a significant positive effect on DLco (p < 0.005) and vital capacity (VC) (p < 0.05) at the end of 1 year.\textsuperscript{30} The recent ATS/ERS position statement, after much discussion, concluded that NAC alone should not be considered in the majority of patients with IPF without additional data from well-designed studies.

The interpretation of these data has been quite controversial. Some have suggested that the magnitude of the treatment effect, although statistically significant, is modest.\textsuperscript{31} Others have suggested that NAC may be modulating potential toxic effects of AZA-PRED alone,\textsuperscript{32} supporting the investigation of NAC as stand-alone therapy.
The IPFnet is now completing the PANTHER-IPF trial with a 1:1 randomization (NAC vs. placebo) and a simple, practical, feasible, and scientifically rational design that will establish standard of care with NAC for IPF based on a currently available therapeutic agent and the existing data to support its use. We anticipate that all future clinical trials of novel therapeutic agents will be tested against this to-be-established standard of care.

3.6. Rationale for the Study Design and Primary Endpoint

The optimal study design of a therapeutic trial in IPF would include survival as a primary endpoint. The published results of the IFN-γ 1b Phase 3 (GIPF-001) trial suggested a survival benefit in subjects with milder disease in retrospective analyses, although the trial was underpowered to address this question. This was likely related to the limited mortality in the PL arm of the study, which included IPF subjects with mild to moderate disease. This study documents that an IPF study powered to improve survival in a patient population with mild disease requires a larger sample size and/or duration of study. In fact, the recently aborted Phase 3 IFN-γ 1b (GIPF-007; INSPIRE) study was a survival-based study and recruited more than 800 subjects at 75 centers worldwide. As such, within the context of the current IPFnet trial, survival is an impractical primary endpoint variable.

Several groups have published data defining an appropriate surrogate outcome variable; a 10% decrement in FVC during 6 to 12 months is a powerful predictor of survival in IPF. Furthermore, additional evidence suggests a similar predictive ability for a 10% decrement in FVC during 3 months of follow-up. With strong supportive evidence of FVC progression being related to mortality on a per-subject basis, this study will use FVC changes in liters between treatment groups as the primary endpoint. Previously published IPF studies have shown a steady decline in FVC (and FVC%pred) among control group subjects. The GIPF-001 study suggested a 48-week decrease in FVC of 0.16 L in the PL-treated subjects. The IFIGENIA study demonstrated a decline in FVC of approximately 0.19 L over 52 weeks in the subjects randomized to the control treatment. Figure 1 depicts the change in FVC for control groups from previously published IPF studies. Based on these data, we expect that the PL group will have a decline of 0.20 L over the 60-week study period. The IPFnet Steering Group determined that a clinically meaningful improvement would be the preservation of the majority of the 0.20-L FVC decline. Therefore, a mean treatment difference of 0.15 L in mean FVC over the 60-week study period was determined to be a clinically meaningful difference.
Recent data suggest that various patient subgroups would be expected to potentially exhibit differential response to therapy. These parameters will be used to a priori separate patients by a series of baseline characteristics, including:

1. Higher enrollment FVC\(^1,2\)
2. Typical vs. atypical high-resolution computed tomography (HRCT) reading at baseline\(^3\)
3. Recent vs. more remote diagnosis (time from initial diagnosis of IPF ≤ 1 year and > 1 year)
4. Lower CPI score at enrollment\(^4\)
5. Medical therapy for gastroesophageal reflux\(^5\)
6. Ethnic background
7. Sex
8. Smoking history (current or ex-smoker vs. never smoker), given potential impact on oxidant status\(^6\)
9. Presence of emphysema > 25% on HRCT

3.7. Rationale for Blinding of Treatments

The issue of treatment blinding was given a great deal of consideration, with subject safety being the primary concern. After discussion among the Steering Group members, it was decided that, as long as subject safety could be ensured, blinding was necessary. Blinding allows the study to:

- Have optimal scientific validity and potential to impact the standard of care for subjects.
• Make objective assessments of treatment effects.
• Maintain clinical equipoise among investigators.
• Encourage subjects to have similar levels of contact with the medical community.
• Minimize the differential dropout rates across study arms.
4. Methods

4.1. Inclusion Criteria

1. Age 35 to 85 years, inclusive
2. FVC ≥ 50% of predicted (post-bronchodilator measurement from the screening visit)
3. DLCO ≥ 30% of predicted (hemoglobin corrected and altitude corrected if >4000 ft above sea level)
4. Ability to understand and provide informed consent
5. Diagnosis of IPF according to a modified version of the ATS criteria ≤ 48 months from enrollment. The date of diagnosis is defined as the date of the first available HRCT or surgical lung biopsy characteristic of definite UIP.

4.1.1. Subjects Shown to Have Usual Interstitial Pneumonia Pattern on Surgical Lung Biopsy

Subjects who have been shown to have UIP pattern on lung biopsy must have all of the following:

1. Exclusion of other known causes of ILD, such as drug toxicity, clinically significant environmental exposures, or diagnosis of connective tissue diseases
2. Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scan

4.1.2. Subjects Who Have Not Undergone a Surgical Lung Biopsy

In addition to the criteria above, these subjects must have radiological findings considered to be definite for the diagnosis of UIP/IPF:

1. Bibasilar reticular abnormalities with minimal ground glass opacities
2. Honeycombing as the predominant feature and located in the peripheral lung bases

4.2. Diagnosis of IPF

Only subjects with definite IPF will be eligible for enrollment in this study. We will utilize a combination of clinical/physiologic features, HRCT, and review of a clinically obtained surgical lung biopsy specimen to establish the diagnosis of IPF. An algorithm for the diagnosis is provided to guide entry into the protocol as outlined in the inclusion and exclusion criteria (Figures 2 and 3). This multi-disciplinary approach uses
expertise from clinicians, radiologists, and pathologists. Investigators at each site, in conjunction with central pathology, will work together to establish the diagnosis of IPF. This interactive approach to the diagnosis of IPF increases the level of agreement between observers.39

A subject with suspected ILD should be evaluated for secondary causes including, but not limited to, environmental exposures, drugs, and systemic diseases. Presence of any of these findings felt to be significant enough to cause an ILD should disqualify the subject from entry into the trial.

If secondary causes are absent, an HRCT scan may be obtained. If an HRCT of sufficiently high quality has been obtained within the last 3 months, that scan may be used for diagnosis. In the appropriate clinical setting, the diagnosis of IPF can be made by the demonstration of a typical radiographic pattern on HRCT or by demonstration of UIP pattern on a surgical lung biopsy. The following criteria for a radiographic (ie, nonsurgical) diagnosis will be used. In the absence of known exposures and/or clinical associations attributable to pulmonary fibrosis, and in the appropriate clinical setting, the presence of definite UIP pattern in HRCT images is required to meet study criteria for the diagnosis of IPF.

Figure 2: Diagnosis of Idiopathic Pulmonary Fibrosis in the IPFnet
Figure 3: Pathology Flow Chart: Surgical Lung Biopsy Diagnosis

**Requirement for diagnosis**

1. **Clinical**: exclusion of other known causes (connective tissue diseases, environmental and drug exposures) of ILD
2. **Radiographic**: HRCT with bibasilar reticular abnormality and honeycomb change with minimal ground glass opacities

**Appropriate clinical setting**

1. Age > 50 years
2. Insidious onset of unexplained dyspnea
3. Duration of illness for ≥ 3 months
4. Bibasilar, inspiratory crackles
Unlike the ATS/ERS consensus criteria published in 2000, bronchoscopy will not be required for diagnosis. This decision was made based on the experience of the IPFnet Steering Group members regarding the utility of bronchoscopy in the diagnosis of IPF. The presence of an atypical HRCT finding will require documentation of a definitive diagnosis by surgical lung biopsy. In fact, this is in keeping with the recently published evidence based guidelines for diagnosis and management of IPF. As shown in Figure 3, central review of the pathology data will be required for a diagnosis of IPF.

We will not require central review of HRCT, as several studies have shown that a confident local interpretation of clinical/HRCT criteria as definite IPF/UIP is associated with a high positive predictive value for finding UIP at surgical lung biopsy (see Table 1). Differences in sensitivity in these series likely reflect subject selection, as Flaherty et al evaluated only UIP and nonspecific interstitial pneumonia (NSIP), while Raghu et al and Hunninghake et al included a broader range of ILD.

<table>
<thead>
<tr>
<th>Researcher</th>
<th># of Subjects</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghu et al</td>
<td>59 (29 UIP by SLB)</td>
<td>78</td>
<td>90</td>
<td>88</td>
<td>82</td>
</tr>
<tr>
<td>Hunninghake et al</td>
<td>91 (54 UIP by SLB)</td>
<td>74</td>
<td>81</td>
<td>85</td>
<td>67</td>
</tr>
<tr>
<td>Flaherty et al</td>
<td>96 (only NSIP &amp; UIP)</td>
<td>37</td>
<td>100</td>
<td>100</td>
<td>30</td>
</tr>
</tbody>
</table>

Abbreviations: PPV, positive predictive value; NPV, negative predictive value; UIP, usual interstitial pneumonia; SLB, surgical lung biopsy; and NSIP, nonspecific interstitial pneumonia.

Furthermore, an analysis of the HRCT scans from subjects enrolled in the GIPF-001 trial confirmed that local site interpretations have a high congruity to a central radiology core. In this multi-center study, 263 HRCT scans were read as definite IPF, and a retrospective central radiology core review found 93.2% to be consistent with IPF. We will also take several additional steps to insure that the local HRCT reads are accurate, including:

1. A detailed training module has been developed and must be completed by each site radiologist before site initiation.
2. Clinical centers are to mail all HRCT scans to the HRCT core lab. The first 10 HRCT scans from subjects enrolled at each enrolling clinical center will be reviewed centrally to be certain that local reads...
are congruent with a central interpretation. If discrepancies are identified, additional education will be provided, and HRCT scans will continue to be reviewed centrally until the central radiology core is confident that the local center is performing appropriately.

3. Random scans will be obtained from each center throughout the study to confirm that the local read continues to agree with central interpretation. If discrepancies are identified, they will be addressed as in #2 above.

In all cases, if a subject has a surgical lung biopsy sample, that sample will be reviewed by the local and central pathologists. Therefore, the only cases that would not be subject to a direct central review process are those where the HRCT meets the centrally defined criteria for an unequivocal diagnosis and a lung biopsy sample is not available. Table 2 below summarizes the possible combinations for making a diagnosis.

**Table 2: Combining HRCT and Pathology Interpretations to Determine if IPF is Present**

<table>
<thead>
<tr>
<th>HRCT Diagnosis</th>
<th>Pathology Diagnosis</th>
<th>Diagnosis of IPF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite UIP</td>
<td>Definite UIP</td>
<td>Yes</td>
</tr>
<tr>
<td>Definite UIP</td>
<td>Probable UIP</td>
<td>Yes</td>
</tr>
<tr>
<td>Definite UIP</td>
<td>Possible UIP</td>
<td>Yes</td>
</tr>
<tr>
<td>Definite UIP</td>
<td>Not UIP</td>
<td>No</td>
</tr>
<tr>
<td>Definite UIP</td>
<td>Unavailable</td>
<td>Yes</td>
</tr>
<tr>
<td>Consistent with UIP</td>
<td>Definite UIP</td>
<td>Yes</td>
</tr>
<tr>
<td>Consistent with UIP</td>
<td>Probable UIP</td>
<td>Yes</td>
</tr>
<tr>
<td>Consistent with UIP</td>
<td>Possible UIP</td>
<td>No</td>
</tr>
<tr>
<td>Consistent with UIP</td>
<td>Not UIP</td>
<td>No</td>
</tr>
<tr>
<td>Consistent with UIP</td>
<td>Unavailable</td>
<td>No</td>
</tr>
<tr>
<td>Inconsistent with UIP</td>
<td>Any</td>
<td>No</td>
</tr>
</tbody>
</table>

Abbreviations: HRCT, high-resolution computed tomography; IPF, idiopathic pulmonary fibrosis;
UIP, usual interstitial pneumonia; Dx, diagnosis

4.3. Exclusion Criteria

1. History of clinically significant environmental exposure known to cause pulmonary fibrosis. Occupational exposures, such as asbestos, or environmental exposure to organic dust, such as occurs in pigeon breeders, may at times mimic the clinical and radiographic findings of IPF.

2. Diagnosis of connective tissue disease, felt by the principal investigator (PI) to be the etiology of the interstitial disease. Diagnosis of collagen-vascular conditions will be according to the published American College of Rheumatology criteria. As such, the presence of any documented collagen-vascular disorder or the presence of any suspicious symptom complex, whether or not associated with significantly abnormal rheumatological serologies, will exclude the subject, at the discretion of the PI.

3. Extent of emphysema greater than the extent of fibrotic change (honeycombing, reticular changes) on HRCT scan.

4. Forced expiratory volume in 1 second (FEV₁)/FVC ratio < 0.65 at screening (postbronchodilator).

5. Partial pressure of arterial oxygen (PaO₂) on room air < 55 mm Hg (< 50 mm Hg at Denver site).

6. Residual volume > 120% predicted at screening (postbronchodilator).

7. Evidence of active infection.

8. Significant bronchodilator response on screening spirometry, defined as a change in FEV₁ ≥ 12% and absolute change > 200 mL OR change in FVC ≥ 12% and absolute change > 200 mL. The percent difference between the FVC (or FEV₁) values will be calculated by taking the absolute value of the difference and dividing it by the larger of the two FVC (or FEV₁) values.

9. Screening and enrollment post-bronchodilator FVC measurements (in liters) differing by > 11%. The percent difference between the FVC values will be calculated by taking the absolute value of the difference and dividing it by the larger of the two FVC values (eg., the percent difference between FVC measurements of 1.9 and 2.0 liters would be determined by taking the difference between the two (0.1 liters) and dividing by the larger of the two (2.0 liters). So 0.1/2.0 = 5%, and these FVC measurements would not exclude the subject.

10. Listed for lung transplantation, i.e., the patient has completed the evaluation process, has been accepted as a candidate for transplantation at an appropriate center, and is waiting to receive notification of an available donor organ.

11. History of unstable or deteriorating cardiac disease.

12. Myocardial infarction, coronary artery bypass, or angioplasty within 6 months of screening.
13. Unstable angina pectoris or congestive heart failure requiring hospitalization within 6 months of screening.

14. Uncontrolled arrhythmia.

15. Severe uncontrolled hypertension.

16. Known HIV or hepatitis C.

17. Known cirrhosis and chronic active hepatitis.

18. Active substance and/or alcohol abuse (as determined by site PI).

19. Pregnancy or lactation (subjects who are pregnant or breastfeeding).

20. Known hypersensitivity to study medication.

21. Any condition other than IPF that, in the opinion of the site PI, is likely to result in the death of the subject within the next year.

22. Any condition that, in the judgment of the PI, might cause participation in this study to be detrimental to the subject or that the PI deems makes the subject a poor candidate.

23. Any therapy directed at pulmonary fibrosis (excepting triple therapy of prednisone plus azathioprine plus NAC) requires a 30-day washout period before randomized. Triple therapy of $\leq$ 12 weeks duration in the past 4 years requires a 30-day washout period before randomization.

24. History of triple therapy of prednisone plus azathioprine plus NAC for $> 12$ weeks’ duration in the past 4 years or previous enrollment in the triple-therapy arm of the PANTHER-IPF study.

4.4. Study Design and Study Visit

4.4.1. Study Design Summary

This study will be a randomized, double-blind, PL-controlled trial designed to assess the safety and efficacy of NAC in subjects with newly diagnosed IPF.

Subjects with mild to moderate IPF (defined as $\text{FVC}\%\text{pred} \geq 50\%$ and $\text{DLCO}\%\text{pred} \geq 30\%$) diagnosed within the past 48 months will be enrolled. Screening will continue until April 30, 2012.
The study will employ a 2-arm design with 1:1 randomization to NAC or PL. Once enrolled, subjects will visit the clinical center at 15 weeks and 15-week intervals thereafter. Each subject will be treated and followed for a maximum of 60 weeks.

During the 60-week visit, subjects will be taken off all study agents. Approximately four weeks after the final dose of study agent is taken, subjects will receive a safety phone call from the study site.

4.4.2. Study Visits

Subjects who meet entry criteria will review the informed consent, a written description of the purpose, procedures, and risks of the study, with the PI, co-investigator, or study coordinator, and all questions will be answered. The informed consent form will be signed by the subject at screening. No protocol-specific procedures will be performed until the subject has signed and dated an informed consent form. This includes the screening procedures.

4.4.2.1. Screening

Once informed consent is obtained, subjects may immediately begin the screening process or may return within 28 days of consent. In the event a study subject has been clinically evaluated at the study site by an IPFnet study physician and has performed testing within three weeks for this clinical evaluation that meets guidelines provided in the IPFnet PANTHER-IPF Manual of Operating Procedures (MOOP), this testing may be used to satisfy the following screening criteria: medical history, physical exam, arterial blood gas (ABG) with A-a gradient, vital signs with oximetry, body height and weight, spirometry, DLCO, lung volumes, and HRCT scan.

Allowing the use of previously performed test results that meet study guidelines for the screening visit is intended to permit subjects easier access to study entry, to prevent subjects from repeating testing that has been performed within the study window, and to decrease risks to subjects from repeated exposure to procedures such as arterial puncture and HRCT.

The following procedures will be performed at screening:

- Medical history and a physical examination
• Measure height and weight
• Serum pregnancy test (if applicable)
• Measure vital signs including oximetry
• Blood draws performed and the following analyses conducted:
  o Hematology (red cell count, white cell count, hemoglobin, hematocrit, cell indices, differential, platelet count)
  o Blood chemistries according to central laboratory protocol (see Section 4.10, Laboratory Testing)
  o Beta human chorionic gonadotropin (serum) pregnancy test (in women of childbearing potential)
  o Urinalysis
• Pulmonary Function Tests (PFTs), including spirometry, pre- and post- bronchodilator, and post-bronchodilator measurement of lung volumes, and measurement of hemoglobin adjusted diffusing capacity.
• Measure ABGs
• HRCT if a satisfactory scan has not been performed on the subject within 3 months of screening (see PANTHER-IPF MOOP for more details)
• Surgical lung biopsies (if applicable) reviewed by local and central pathology departments
• Current medications. If required, a washout period discussed with the subject and initiated at this visit

4.4.2.2. Enrollment

The enrollment visit is expected to take place within eight weeks of the screening visit. Enrollment visit activities include:
• Measure vital signs, including oximetry
• Measure height and weight
• Serum pregnancy test (if applicable)
• If consent has been given, blood will be drawn and a urine specimen collected for the bio-specimen repository
• Spirometry (post-bronchodilator)
• Measure 6MWT with Borg Dyspnea Scale
- Collect Quality-of-life (QOL) data using the SF-36, EuroQol, Investigating Choice Experiments for Preferences of Older People Capability Instrument (ICE CAP), and SGRQ
- Female subjects complete Gender Substudy questionnaire
- Dyspnea status collected using the UCSD SOBQ
- Evaluate Acute Exacerbation (AEx)
- Review of any Adverse Events (AEs)
- Review of concomitant medications
- Subject receives diary and instructions on its purpose and proper use
- Subject receives supply of study drug sufficient to last until his or her 15-week study visit

See the Schedule of Assessments (Table 3) for more details. Subjects with screening and enrollment post-bronchodilator FVC measurements (in liters) differing by more than 11% are not eligible to be enrolled in the study.

Subjects will be asked to provide a physician of record. This physician will be considered the subject’s primary care provider (PCP), and, if the subject agrees, the PCP will be informed by letter of the subject’s enrollment in the trial. The subject will be informed that his or her ongoing medical care should be received from the PCP. The PCP will be informed of any safety issues identified by the study staff. The PCP will also be given information regarding communication with study personnel about pertinent health issues or clinic encounters the subject may have.

4.4.2.3. Week 15

The week 15 visit is expected to occur within +/- 14 days of the subject’s scheduled visit time (eg., the week 15 visit should occur anytime between 13 and 17 weeks after starting study drug Week 15 activities include:

- Measure vital signs with oximetry
- Measurement height and weight
- Serum pregnancy test (if applicable)
- Spirometry (post-bronchodilator) measurement
- Review of AEs
- Evaluate for AEx
• Review concomitant medications
• If consented, draw blood and collect urine specimen for the biospecimen repository
• Subjects return used and unused study drug for the visit
• Review study diary and a new study diary will be given
• Provide additional supply of study drug sufficient to last until the next scheduled visit

4.4.2.4. Week 30

The week 30 visit is expected to occur within +/- 14 days of the subject’s scheduled visit time (eg., the week 30 visit should occur anytime between 28 and 32 weeks after starting study drug). Week 30 activities include:

• Physical examination
• Measure vital signs with oximetry
• Measure height and weight
• Laboratory values (complete blood count [CBC] and serum chemistries)
• Serum pregnancy test (if applicable)
• Measure spirometry (post-bronchodilator)
• 6MWT with Borg scale
• DLCO
• Review of AEs
• Evaluate for AEx
• Review concomitant medications
• Complete all QOL and dyspnea questionnaires (EuroQol, ICE CAP, SF-36, SGRQ, and UCSD SOBQ).
• If consent has been given, blood will be drawn and a urine specimen collected for the biospecimen repository
• Review study diary
• Subjects return used and unused study drug for the visit
• Provide additional supply of study drug sufficient to last until the next scheduled visit

4.4.2.5. Week 45
The week 45 visit is expected to occur within +/- 14 days of the subject’s scheduled visit time (e.g., the week 45 visit should occur anytime between 43 and 47 weeks after starting study drug). Week 45 activities include:

- Measure vital signs with oximetry
- Measure height and weight
- Serum pregnancy test (if applicable)
- Measure spirometry (post-bronchodilator)
- Review of AEs
- Evaluate for AEs
- Review concomitant medications
- If consent has been given, blood will be drawn and a urine specimen collected for the biospecimen repository
- Subjects return used and unused study drug for the visit
- Study diary reviewed
- Provide additional supply of study drug sufficient to last until the next scheduled visit

4.4.2.6. Week 60 (Early Withdrawal or Final Treatment Visit)

At week 60, or at subject withdrawal from the study (premature, by study doctor or subject’s decision), a final treatment visit will occur. At this final treatment visit subjects will discontinue NAC/PL abruptly. Week 60 activities also include:

- Physical examination
- Measure vital signs with oximetry
- Measure height and weight
- Laboratory values (complete blood count [CBC] and serum chemistries)
- Spirometry (post-bronchodilator) measurement
- 6MWT with Borg scale measurement
- DLCO
- Lung volumes
- ABG
- Review of AEs
• Evaluate for AE x
• Review concomitant medications.
• Subjects will complete all QOL and dyspnea questionnaires (EuroQol, ICE CAP, SF-36, SGRQ, and UCSD SOBQ)
• If consent has been given, blood will be drawn and a urine specimen collected for the biospecimen repository
• Subjects return used and unused study drug for the visit
• Study diary reviewed

4.4.2.7. Final Site Visit – FVC drop confirmation

In the event that the subject has a recorded FVC drop of >10% from baseline at the final treatment visit and the subject has not had a confirmation of such a drop at a previous study visit, the subject should return to the clinical site 6 to 8 weeks after the final treatment visit. During this visit, a post-bronchodilator spirometry test will be performed. This FVC measurement will be evaluated according to section 5.2.1 of this protocol.

4.4.2.8. Final Visit – Telephone Follow-up

Four weeks following the final dose of study medication, subjects will receive a telephone call from the study coordinator to ensure that there are no side effects and to follow up on any ongoing adverse events (AEs).

4.4.2.9. Phone Contact Between Visits

At week 2 and each month that a subject does not have a scheduled clinical center visit, his or her study coordinator will contact him or her at least once by telephone to:

• Inquire if the subject has had any hospitalizations, events that might be considered an AE, or any events significant enough to warrant an out-of-cycle visit to the clinical center.
• Remind subjects of their current dosage levels and confirm that the subject understands them.
• Address any questions or concerns the subject might have regarding other aspects of the study.
• Assess adherence to the treatment regimen by reviewing diary data; verbal review of medications taken, including nutritional supplements.
### Table 3: Schedule of Assessments

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Screening Visit 0</th>
<th>Enrollment Visit 1</th>
<th>Week 15 Visit 2</th>
<th>Week 30 Visit 3</th>
<th>Week 45 Visit 4</th>
<th>Week 60 / Early Withdrawal Visit 5</th>
<th>Final1 Visit (via phone)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum pregnancy test (if applicable)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Review of lung biopsy</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial Blood Gas</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-Minute Walk Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Vital signs with oximetry</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Body height and weight</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Complete Blood Count</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Chemistry panel</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monitor Lab Values</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Specimen repository substudy blood draw and urine collection (if consented)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRCT (if not completed within three months)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spirometry (pre- and post-bronchodilator)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spirometry (post-bronchodilator only)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLCO (post-bronchodilator only)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung volumes (post-bronchodilator only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaluate for acute exacerbation</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Review Adverse Events</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Review concomitant meds</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Dispense subject diary</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dispense study agent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender Substudy questionnaire (female subjects only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EuroQol, ICECAP, UCSD SOBQ, SGRQ, SF-36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** DLCO, diffusing capacity of the lung for carbon monoxide; QOL, Quality of Life; ICECAP, Investigating Choice Experiments for Preferences of Older People; UCSD SOBQ, University of California Shortness of Breath Questionnaire; SGRQ, St. George’s Respiratory Questionnaire; SF-36, Short Form 36 Health Survey

1Follow-up visit via phone will occur four weeks after final dose of study medication
4.5. Dose Justification

The general philosophy for determining dosing levels was to apply previously examined treatment regimens. With the focus of the study being to establish a standard of care for mild/moderate IPF subjects, the goal was to develop flexible yet standardized treatment rules that allow for the temporary or permanent withholding of one or more components of treatment when necessary. Subjects developing laboratory abnormalities or symptoms that result in discontinuation of one or more components of study treatment may continue on the other components as long as there is no contraindication for this. Complete follow-up is important for the validity of any study. As a strategy to maintain protocol adherence, we are using a treatment regimen that will detect potential side effects and prompt interventions proactively in the interest of patient safety. In addition, subjects who permanently stop study medications during the course of the study are encouraged to continue in the study, completing all scheduled visits and tests.

4.5.1. Rationale for N-acetylcysteine Dosing

To our knowledge, there have been no IPF studies to correlate clinical outcome measures with different dosages for NAC. The dosage chosen is based on the IFIGENIA study. However, BAL lung GSH levels from subjects with IPF have been augmented with the use of oral NAC at 600 mg 3 times per day. In addition, lung GSH levels have been associated with improved PFTs. The dose chosen for this study was based on previous data, including the IFIGENIA study.

4.5.1.1. Dosing of N-acetylcysteine/placebo

Dosing of NAC/PL will be 600 mg orally 3 times a day (1800 mg/day).

4.5.1.2. Reasons to Discontinue N-acetylcysteine/placebo

NAC/PL may be temporarily or permanently discontinued for the duration of the study for gastrointestinal symptoms or dermatologic reactions.
Temporarily discontinue (hold) oral NAC/PL for subjects requiring inpatient admission for acute exacerbation (AEx) or other conditions. Resume NAC/PL after discharge.
4.5.2. Dosage Algorithms

Dosage Adjustment Algorithm #1: NAC/PL Dose Modifications for Gastrointestinal Symptoms: Nausea, Vomiting, Abdominal Discomfort, Diarrhea

GI Symptoms determined by the PI to be clinically significant: Nausea, Vomiting, Abdominal Discomfort, Diarrhea

NAC/PL: Temporarily d/c (HOLD) x 3 Days

- Monitor symptoms, intervene as clinically indicated (eg, fluid replacement, antidiarrhea or antinausea medication)
- Monitor or lab PRN

Are symptoms resolving after 3 days? NO

Symptoms NOT resolving after 3 days of holding study medication:
- Assessment/management per clinical discretion of investigator.
- Likely not study medication, discuss resuming study medication with medical monitor when symptoms resolved.

YES

Temporarily d/c (HOLD) NAC/PL for 4 additional days (total hold 1 week), then:
NAC/PL: Resume 600 MG TID

Did symptoms recur? YES

STOP
NAC/PL for duration of study

NO

NAC/PL: No Change
Dosage Adjustment Algorithm #2: NAC/PL Dose Modifications For Dermatologic Reactions

**Dermatologic Reactions (Not Acneiform) ≥ Grade 2**

NAC/PL: Temporarily d/c (HOLD) x 3 days

**Are symptoms resolving after 3 days?**

**YES**

Temporarily d/c (HOLD) NAC/PL for 4 additional days (total hold 1 week), then:
- NAC/PL: resume 600 MG TID

**NO**

Symptoms not resolving after 3 days of holding study medication:
- Assessment/management per clinical discretion of investigator.
- Likely not study medication.
- Discuss resuming study medication with medical monitor when symptoms resolved.

**Grading per Common Terminology Criteria for Adverse Events V3.0** ([http://ctep.cancer.gov](http://ctep.cancer.gov))

For example:
- **Grade 1 RASH/DESQUAMATION**: Macular or papular eruption or erythema without associated symptoms.
- **Grade 2 RASH/DESQUAMATION**: Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering <50% of body surface area.

**Did symptoms recur?**

**YES**

STOP
NAC/PL for duration of study

**NO**

NAC/PL: No change
4.6. Contraindications, Precautions, and Side Effects of Study Medications

4.6.1. Contraindication
Contraindication to NAC is known hypersensitivity to it.

4.6.2. Precautions
Concomitant administration of oral NAC and antibiotics has shown a slightly reduced absorption of cephalexin and a slight increase in erythromycin serum levels. NAC contains free sulfhydryl groups. There is no evidence that individuals sensitive to sulfa drugs are sensitive to NAC.

The NAC preparation being administered in this study contains 20 mg of aspartame. Because of the phenylalanine component of aspartame, individuals with phenylketonuria should avoid or restrict aspartame intake to avoid increased blood levels of phenylalanine. Because of this risk, labeling is required on all products containing aspartame.

4.6.3. Side Effects
Side effects of NAC range from common to serious. See Table 4.
Table 4: Side Effects of NAC

<table>
<thead>
<tr>
<th>Undesirable Effects</th>
<th>Uncommon (≥1/1,000; &lt;1/100)</th>
<th>Rare (≥1/10,000; &lt;1/1,000)</th>
<th>Very rare (&lt;1/10,000)</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td>Hypersensitivity</td>
<td></td>
<td>Anaphylactic shock / reaction</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Tinnitus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td></td>
<td>Bronchospasm, Dyspnea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders*</td>
<td>Vomiting, diarrhea, stomatitis, abdominal pain, nausea</td>
<td>Dyspepsia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Urticaria, rash, angioedema, itching</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Pyrexia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Reduced arterial pressure</td>
<td></td>
<td>Face edema</td>
<td></td>
</tr>
</tbody>
</table>

*In very rare cases the onset of severe skin reactions, such as Stevens-Johnson syndrome and Lyell syndrome, was reported to have a temporal relationship with N-acetylcysteine administration. Although in most cases at least another suspect drug probably most involved in the genesis of the above mentioned mucocutaneous syndromes has been identified, in case of mucocutaneous alterations it is appropriate to contact one’s doctor, and the administration of N-acetylcysteine should be immediately discontinued.

Some studies confirmed a reduction of platelet aggregation during N-acetylcysteine administration. The clinical significance of these findings has not been defined yet. [Source: Fluimucil Investigator Brochure]

### 4.7. Recruitment Procedures

Subjects recruited for this study will be established patients of the investigators or physician- or self-referred to participating clinical centers in the IPFnet. Each clinical center within IPFnet has a well-developed infrastructure of local pulmonologists within the surrounding geographic area. These pulmonologists are kept informed of ongoing IPF clinical trials and regularly refer subjects to studies conducted at IPFnet clinical centers.

Additional steps will be taken to inform clinicians of the trials in progress within IPFnet, including: presentations at faculty staff meetings at local hospitals, medical grand rounds, and national conferences; direct mail notification; monthly faxes; and advertisement of network trials.
in pulmonary journals. Clinical center patients previously diagnosed with IPF will be notified of the trials by mail whenever possible.

Recruitment of minorities and women will be monitored by the DCC and DSMB. If necessary, additional recruitment efforts will be made at specific centers to ensure that the aggregate subject sample contains appropriate representation of women and minorities.

4.8. Study Procedures

The following procedures are detailed in the PANTHER-IPF MOOP accompanying this protocol:

1. PFT
2. ABG
3. HRCT scan of the chest (including imaging of pulmonary arteries)
4. CBC and serum chemistries
5. Pregnancy test
6. 6MWT/Borg Dyspnea Scale
7. QOL questionnaires (EuroQol, HAD, SF-36, SGRQ, and ICE CAP)
8. UCSD SOBQ
9. Gender Substudy Questionnaire

All assessments of PFTs will be conducted by study personnel not directly involved in the treatment of the subjects.

4.8.1. Biological Specimen Management

4.8.1.1. Biological Specimen Sample Management

Subjects at clinical centers participating in the specimen repository substudy who consent to having blood drawn for research purposes and for the banking of blood, blood components, and other biologic specimens (urine and BAL fluid) will have approximately 40.5 mL of blood
drawn, 17 mL blood drawn for DNA, and 20 mL of urine collected at enrollment visit. Subjects will have approximately 50 mL of blood drawn and 20 mL of urine collected at each 15-week follow-up visit. Blood specimens will be separated according to PANTHER-IPF MOOP guidelines into the following components for banking in the repository: serum, plasma, and DNA. Coding of all biologic specimens for the repository will be performed by study staff at the clinical center. The samples will be processed per PANTHER-IPF MOOP guidelines, aliquoted, labeled with barcode labels, and stored at -70°C at the clinical center, and shipped to the central repository.

The only subject identifiers will be a sample ID number and subject initials. This sample ID will be linked in the IPFnet DCC clinical database to subject information. No subject information will be transferred to the biological-specimen database.

The subject’s samples may be used for approved sub-studies relating to human disease, including, but not limited to IPF. The studies for which an individual’s samples will be made available will be determined by the subject’s answers to questions on the biological-sample informed consent form. The subjects can choose to make their samples available for all options or any combination. Samples will be made available to researchers only with IPFnet Steering Group approval until such time as the samples are made public through the NHLBI repository.

4.9. Concomitant Medications

Concurrent treatment with FDA-approved therapy for IPF is allowed. Colchicine may be used for treatment of gout. Temporary treatment with oral or IV corticosteroids for clinical worsening or suspected AEx is permitted. Nutritional supplements containing NAC are not allowed.

4.10. Laboratory Testing

Clinical laboratory parameters will be assessed at screening and at the end of the study. The following tests will be performed at the two time points specified in the protocol: chemistry (A/G ratio, ALT [SGPT], AST [SGOT], albumin, alkaline phosphatase, amylase, bilirubin-direct,
bilirubin-indirect, bilirubin-total, BUN, BUN/creatinine ratio, calcium, carbon dioxide, cholesterol-total, chloride, CPK-total, creatinine, GGT, globulin, glucose, iron-total, LDH, lipase, magnesium, phosphorus-inorganic, potassium, protein-total, sodium, TIBC, triglycerides, uric acid) and hematology (red blood cell count, WBC count, hemoglobin, hematocrit, cell indices, differential, platelet count).

4.11. Blinding of Study Drugs

Subjects and caregivers will be blinded to study treatment. Every subject will receive NAC or matching PLs at every study visit from the baseline visit to the week-45 visit. No study agent will be dispensed at the week-60 visit.
5. Study Endpoints

5.1. Primary Study Endpoint

The primary endpoint will be the change in serial measurements of FVC over the study period.

5.2. Secondary Study Endpoints

5.2.1. Time to Disease-progression

The time-to-death or a 10% decline in FVC will be defined as the time-to-disease progression. The 10% decline in FVC from enrollment must be confirmed on 2 consecutive visits no less than 6 weeks apart. For subjects with 2 consecutive visits with a 10% decline in FVC, the time-to-disease progression will be defined as the time interval between enrollment and the initial visit with a 10% FVC decline. For subjects who experience disease progression, the study doctor will determine whether or not the subject will remain in the study.

5.2.2. Acute Exacerbations

The following 3 criteria will define AEx in subjects with acute worsening of their respiratory conditions:

1. Clinical (all of the following required):
   A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., emergency room, clinic, study visit, hospitalization).
   B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea.
   C) No pneumothorax.
2. **Radiologic/Physiologic** (A and B required):
   A) New ground glass opacity or consolidation computed tomography (CT) scan, OR new alveolar opacities on chest x-ray.
   B) Decline of $\geq 5\%$ in resting room air SpO$_2$ from last recorded level OR decline of $\geq 8$ mm Hg in resting room air PaO$_2$ from last recorded level.

3. **Microbiologic** (all of the following required):
   A) No clinical evidence for infection (i.e., absence of grossly purulent sputum, fever $> 39^\circ$C orally).
   B) Lack of positive microbiological results (if done) from lower respiratory tract defined as:
      (1) Clinically significant bacterial growth on sputum or endotracheal aspirate cultures;
      (2) Quantitative culture by protected brush specimen $\geq 10^3$ cfu/mL or BAL $\geq 10^4$ cfu/mL;
      (3) The presence of specific pathogens on stains of any of the above.
   C) Lack of positive pathogen in blood cultures (if done).

**Identification of Acute Exacerbations**

All subjects will be educated about the importance of identifying AExs. At the time of enrollment, subjects will be told about the possibility of developing acute symptomatic worsening that might represent an AEx of IPF, and instructed to contact their study clinical center coordinator within 48 to 72 hours of the apparent event.

All subjects will be contacted by phone monthly, and questioned about any change in dyspnea or cough and any interim clinic visits or hospitalizations. Finally, as part of the IPFnet outreach to community referring physicians, the importance of AExs will be emphasized. When a subject is identified who meets criterion 1A, this will trigger the collection of additional clinical data to evaluate a suspected AEx. These data will be collected as part of standard clinical care (i.e., this protocol does not require collection of all items). The additional items to be collected for suspected AEx include:

- IPFnet AEx case report form (eCRF) (required)
• Chest x-ray, CT scan with/without pulmonary angiogram (reports should be faxed and followed by the hard copies/discs)
• Oxygen saturation (pulse oximetry)
• ABG
• Respiratory cultures (sputum, endotracheal aspirate, lavage)
• Blood cultures
• Clinic/hospital records related to the event

All potential cases of AEx will be reviewed by the clinical center PI first, and a decision on whether the case may represent an AEx will be made. If AEx is suspected, the case will be sent to the IPFnet adjudication committee, which will assign a final diagnosis (see Table 5). If there is disagreement among members, the majority opinion will be recorded.

During episodes of suspected AEx, as determined by the individual clinical center investigator, subjects will remain blinded and in the study.

Table 5: Final Diagnoses in Evaluation of Suspected Acute Exacerbations

<table>
<thead>
<tr>
<th>Definite acute exacerbation</th>
<th>All criteria met; no alternative etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unclassifiable acute worsening</td>
<td>Insufficient data to evaluate all criteria; no alternative etiology</td>
</tr>
<tr>
<td>Not acute exacerbation</td>
<td>Alternative etiology identified that explains acute worsening</td>
</tr>
</tbody>
</table>

Management of the suspected AEx will be at the discretion of the treating physician. Standard of care generally involves evaluation for respiratory infection, pulmonary embolism, cardiac events and pneumothorax, and treatment with IV corticosteroids.

Study drugs will be resumed at pre-suspected AEx doses after subjects clinically improve as confirmed by the local PI. All subjects should be seen at the clinical center within 2 to 4 weeks of recovery for measurement of post-bronchodilator FVC (see Figure 4). Subjects unable to return to the clinical center after suspected AEx due to medical frailty (e.g., continued
institutionalization, progressive disability) will be categorized as failing to maintain FVC response in secondary analyses.

Figure 4. Acute Exacerbation Flow Chart

5.2.3. Respiratory Infections

An upper respiratory infection will be defined as:

- Change in sputum discoloration
- Increased cough of no more than 14 days’ duration

A lower-respiratory infection (pneumonia) will be defined as new segmental or lobar airspace opacities visualized by image studies (chest radiograph or HRCT) in addition to any of the following:

- Positive pathogen/cultures in good sample of sputum or lower-airway secretions retrieved by fiberoptic bronchoscope
- Fever > 39°C or > 100°F
- Leukocytosis > 12,000 (unexplained; no increase in dose of corticosteroids)
5.2.4. Maintained FVC Response

Subjects with follow-up FVC%pred measurements at or above their baseline FVC%pred level will be classified as having maintained FVC response. Subjects with reduced FVC%pred levels or missing data for any reason, including death or medical frailty, will be classified as having not maintained FVC response. The FVC%pred value is used because unadjusted FVC measurements are expected to decline with age.
6. Safety Evaluations and Procedures

6.1. Adverse Events

During a clinical trial, the reporting of adverse experience information can lead to important changes in the way a new treatment is developed, as well as provide integral safety data.

6.1.1. Definitions

An advers event (AE) is any untoward medical occurrence in a subject or clinical investigation subject who was administered a pharmaceutical product. The AE does not necessarily have to have a causal relationship with the drug administered. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. Diseases, signs, symptoms, or laboratory abnormalities already existing at enrollment are not considered AEs unless they worsen (ie, increase in intensity or frequency). Surgical procedures themselves are not AEs; they are therapeutic measures for conditions that require surgery. The condition for which the surgery is required may be an AE. Surgical procedures planned before randomization and the conditions necessitating the surgery are not AEs.

A serious adverse event is any untoward event that:

- Is fatal
- Is life-threatening
- Requires inpatient hospitalization or prolongation of existing hospitalization, with the following exceptions:
  - Preplanned (before the study) hospital admissions, unless the hospitalization is prolonged
  - Planned admissions (as part of a study, eg, routine biopsies)
  - Hospitalization lasting < 24 hours
Hospitalization for elective procedure
Emergency room visits
• Results in persistent or significant disability or incapacity
• Is a congenital anomaly or birth defect
• Important medical events that may not result in death, be life-threatening, or require inpatient hospitalization may be considered serious adverse events (SAEs) when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.

Life-threatening means that the subject was, in the view of the investigator, at immediate risk of death from the AE as it occurred. It does not include an AE that, had it occurred in a more severe form, might have caused death.

Persistent or significant disability/incapacity means that the event resulted in permanent or significant and substantial disruption of the subject’s ability to carry out normal life functions.

Causality:
A reasonable possibility means the AE may have been caused by/related to the study drug. A perceived or real lack of efficacy does not satisfy the definition of relatedness.

6.1.2. Adverse Event (AE) Reporting

For the PANTHER-IPF trial, all AEs (serious and nonserious), occurring from randomization through final study visit (4 weeks after final dose of all study medication) will be recorded on the AE page of the case report form (CRF)

6.1.2.1. Serious Adverse Events (SAE) Reporting

For this trial, all deaths and all SAEs, which occur from randomization through final study visit, must be entered within the EDC system, via the SAE eCRF page within 24 hours of the investigative site’s knowledge of the event. It is the responsibility of the clinical center
investigator to provide a causality assessment of the event for each study medications based upon the information available at the time of the report. It is understood that complete information about the event may not be known at the time the initial report is submitted. In the event the EDC system is not accessible to the site at the time of event reporting, investigative sites will complete and forward a paper back-up SAE form to DCRI Safety Surveillance for processing:

**DCRI Safety Surveillance**

**Telephone:** 1-919-668-8624 or 1-866-668-7799 (toll free)

**Fax:** 1-919-668-7138 or 1-866-668-7138 (toll free)

The investigator must complete and submit follow-up SAE information via the eCRF when important new or follow-up information (e.g., final diagnosis, outcome, results of specific investigations) becomes available. Follow-up information should be submitted according to the same process used for reporting the initial event as described above. All SAEs will be followed until resolution, stabilization, or 30 days after the subject has completed the final visit (4 weeks after the final dose of study medication), whichever occurs first. The investigator is responsible for reporting SAEs to their institutional review board (IRB) per site specific IRB reporting guidelines.

**6.1.2.2. Regulatory Reporting**

AEs that are serious, study drug related, and unexpected will be reported to the regulatory authorities. The DCRI Safety Surveillance medical monitor will perform a medical review of all SAEs submitted and evaluate for “unexpectedness.” DCRI Safety Surveillance will prepare MedWatch reports for those events identified as serious, study drug related and unexpected as determined by Safety Medical Monitor.

DCRI Regulatory Services will submit all unexpected, study drug-related SAEs as per 21 CFR 32. DCRI Safety Surveillance will provide a safety alert letter to the NHLBI, DSMB, and DCC clinical operation (for distribution to sites) within 15 days of initial receipt of the information.
Investigators are responsible for promptly reporting these events to their reviewing IRBs according to site specific IRB reporting guidelines.

**6.2. Clinical Medical Monitoring**

There will be an unblinded physician at the IPFnet DCC serving as medical monitor. The medical monitor will be available to assist with questions about dosage adjustments of study medications, including discontinuation or resumption of medications.

**6.3. Unblinding Procedures**

Unblinding of subjects or investigators to subject treatment is strongly discouraged. For ongoing clinical management, all subjects should be presumed to be receiving “active” study drug. To ensure the subject’s safety, the study treatment will be dose-adjusted based on laboratory test results, clinical findings, and symptoms.

The IPFnet DCC medical monitor and PANTHER-IPF co-chairs, Drs. Ganesh Raghu and Fernando Martinez, will be available to the study physicians to discuss study drug management on a case-by-case basis. Un-blinding will be considered ONLY when the knowledge of subject treatment assignment is ABSOLUTELY ESSENTIAL for subject safety and after discussion of the subject’s case with the medical monitor and either Dr. Raghu or Dr. Martinez. Unblinding of study treatment should be minimized during the conduct of the trial. In those cases where it is felt to be medically necessary the DCC medical officer will communicate directly with the managing physician to minimize unblinding of study personnel.
7. Study Drug Procedures

At the baseline, 15-week, 30-week, and 45-week study visits, subjects will receive a supply of study drug sufficient to last until the next visit at which study drug will be dispensed.
8. Data Management

8.1. Hardware and Software Configuration

8.1.1. Hardware and Database Software

Data will be stored in an Oracle database system. Oracle has advantages of processing efficiency and smooth linkage with other software systems. The application and database will be hosted on Solaris Unix servers at the IPFnet DCC.

8.1.2. Statistical Software

SAS will be used as the principal application for the management of analysis data files and statistical computations. S-Plus will be used to provide supplementary functions as needed.

8.1.3. Access Control and Confidentiality Procedures

Access to databases will be controlled centrally by the IPFnet DCC through user passwords linked to appropriate privileges. This protects the data from unauthorized changes and inadvertent loss or damage.

8.1.4. Security

Database and Web servers will be secured by a firewall and through controlled physical access. Oracle has many security features to ensure that any staff member accessing the database has the proper authority to perform the functions he or she requests of the system. Within the secondary SAS databases, Unix group-access control maintains similar security. The Sun workstation login is secured by extensive user-password facilities under Unix.
8.1.5. Back-up Procedures

Database back-up will be performed automatically every day, and standard IPFnet DCC policies and procedures will be applied to dictate tape rotation and retention practices.

8.1.6. Virus Protection

All disk drives that provide network services, and all user computers, will be protected using virus-scanning software. Standard IPFnet DCC policies will be applied to update these protection systems periodically through the study.

8.2. Sources of Data

8.2.1. Design and Development

The IPFnet DCC will be responsible for development of the electronic case report forms (eCRFs), development and validation of the clinical study database, ensuring data integrity, and training clinical center staff on applicable data management procedures. A web-based distributed data entry model will be implemented. This system will be developed to ensure that guidelines and regulations surrounding the use of computerized systems used in clinical trials are upheld. The remainder of this section provides an overview of the data management plan associated with this protocol.

8.2.2. Data Collection Forms

The data collection process consists of direct data entry at the study clinical centers into the EDC system(s) provided by the DCC. A data collection worksheet will be provided to clinical centers for recording data in the event the EDC system is unavailable. Data entry of the eCRFs should be completed according to the instructions provided and project specific training. The investigator is responsible for maintaining accurate, complete and up-to-date records, and for ensuring the completion of the eCRFs for each research participant.
8.2.3. Data Acquisition and Entry
Data entry into eCRFs shall be performed by authorized individuals. Selected eCRFs may also require the investigator’s written signature or electronic signature, as appropriate. Electronic CRFs will be monitored for completeness, accuracy, and attention to detail during the study.

8.2.4. Data Center Responsibilities
The IPFnet DCC will 1) develop a data management plan and will conduct data management activities, 2) provide final eCRFs for the collection of all data required by the study, 3) develop data dictionaries for each eCRF that will comprehensively define each data element, 4) conduct ongoing data monitoring activities on study data, 5) monitor any preliminary analysis data cleanup activities, and 6) rigorously monitor final study data clean up.

8.2.5. Data Editing
Completed data will be entered into the IPFnet DCC automated data acquisition and management system. If incomplete or inaccurate data are found, a data clarification request will be generated and distributed to clinical centers for a response. Clinical centers will resolve data inconsistencies and errors and enter all corrections and changes into the IPFnet DCC automated data acquisition and management system.

8.2.6. Training
The training plan for clinical center staff includes provisions for training on assessments, eCRF completion guidelines, data management procedures, and the use of computerized systems.
9. Study Design and Data Analysis

9.1. General Analytic Considerations

All primary analyses will be based on intent-to-treat (ITT) principles using all randomized subjects. Baseline factors across groups will be compared using mean (standard deviation) and median (25th and 75th percentiles) summary measures. Kaplan-Meier curves will be used to display event rates. Due to clinical interest in departures from both sides of the null hypothesis, all test statistics will be 2-sided.

Reasonable caution needs to be taken when conducting multiple analyses on key clinical subgroups. For subgroup analyses, a conservative significance level of 0.001 will be used for all interaction tests. Thus, subgroup comparisons will be considered exploratory unless the p-value from the interaction test is smaller than 0.001.

9.2. Randomization, Blinding, and Reporting of Results

A permuted block-randomization scheme will be created with varying block sizes stratified by clinical center. Once a subject has completed the screening and baseline period and evaluation for inclusion/exclusion criteria, the randomization process will begin. Subjects will be randomized to receive NAC or matching placebo with equal probability (1:1), via telephone contact with a central interactive voice response system (IVRS), using a toll-free randomization number. On the day of randomization, after the subject has successfully met all inclusion and exclusion criteria, the investigator or designee will call the central randomization number to obtain the assigned kit randomization numbers for that subject. At each subject visit, the investigator or designee will call the central randomization number to obtain the new kit randomization numbers for resupply of the subject. For resupply of the clinical center, the IVRS will monitor minimal volume of a kit type and/or expiration date and will automatically notify the pharmacy.
The trial results will be reported according to guidelines specified in the CONSORT statement. A flow diagram describing screening, recruitment, randomization, dropout, and vital status will be included in the primary manuscript. AEs and efficacy data will be presented for all treatment groups. Adherence, dropout, and lost to follow-up will be carefully examined across all treatment groups. Analyses of safety will be based on data from all randomized subjects who received at least one dose of study drug.

9.3. Stratification

Subjects will be distributed to the two treatment arms in a 1:1 allocation ratio. Stratification blocks will be based on clinical centers.

9.4. Specification of the Primary Analyses

A mixed model repeated measures (MMRM) analysis, described in section 9.5, will be used to compare differences in the slope of FVC measurements across the treatment groups. Response variables are values of the FVC measured at baseline and every 15 weeks until study completion. Variables in the model will include: treatment, time, and time by treatment, age, sex, race, and height. Contrast estimates of differences in slopes of treatment over time (along with confidence intervals) will be used to estimate the treatment effect. The validity of this model in terms of meeting modeling assumptions will be assessed via standard modeling diagnostics and goodness-of-fit measures. Based on the MMRM framework, missing FVC data will not be imputed for the primary analysis.

9.5. Analysis of Longitudinal Endpoints

A common goal in clinical trials is to specify models that are easily implemented and reproducible by independent data analysts. On the other hand, the models should have proper statistical behavior in terms of low bias and high precision. Many common approaches to longitudinal data analysis including last observation carried forward (LOCF) imputation rely on the missing completely at random (MCAR) assumption. However, the MCAR assumption is
unlikely to hold in many clinical trials because missing data are often related to disease progression and prognosis. A more reasonable assumption, missing at random (MAR), specifies that the complete data distribution can be modeled using only the observed data. The likelihood-based MMRM approach is valid under the more general MAR assumptions. These models will be applied to analyze the longitudinal data secondary endpoints.

The advantages of MMRM analysis are that all important characteristics of the model can be pre-specified, standard software can be used to implement the models, and results are based on ITT principles.\textsuperscript{43} In addition, the MMRM approach offers superior control of Type I and Type II errors compared with the LOCF approach.

Response variables are values of the PFTs measured at enrollment and every 15 weeks until study completion and 6MWT values measured at baseline, week 30, and week 60. Covariates are treatment, time, time by treatment, and key baseline risk factors. Contrasts (along with confidence intervals) of treatment by time will be used to estimate the treatment effect.

The correlation structure involves multiple pieces, including measurement errors, random variation, and interindividual variability. For the longitudinal data analyses, an unstructured correlation matrix for within-subject errors will be assumed. Other correlation structures, including compound symmetry, will be examined as needed. A careful examination of reasons for study discontinuation will be conducted to assess the validity of MCAR. Sensitivity analyses will be used to examine the untestable assumption that the observed data violate the MAR assumption. The MMRM models will be implemented using PROC MIXED in SAS.


Regression modeling approaches using either the logistic regression model or Cox proportional hazards regression model will be employed when appropriate. The validity of these models will be assessed via standard modeling diagnostics and goodness-of-fit measures. Estimates of cumulative frequencies for more general time-lagged responses will be calculated using the partitioned version of the Bang-Tsiatis estimator.\textsuperscript{44} The partitions will be set at 15-week intervals
to correspond with the data-collection process. Covariate adjusted event rates will be calculated using inverse probability-weighted regression estimates.\textsuperscript{45}

9.7. Power Analysis

9.7.1. Primary Analyses

Based on previously published IPF clinical trials, the PL group is expected to experience a drop in FVC of approximately 0.20 L over the study period (see Figure 1). The IPFnet Steering Group determined a clinically important difference would be to preserve the majority of the decline relative to PL over the study period. In particular, a treatment effect of 0.15 L was determined to be a clinically meaningful difference. Potential dropout is a key factor in the proposed study. The drop-out process assumed 5\% lost to follow-up after every study visit. Only 80\% of subjects were assumed to be followed for the entire study period. All models assumed a compound symmetry structure for the covariance matrix. Power calculations were performed using a SAS IML program for designing repeated measures studies.\textsuperscript{46} Based on preliminary reviews of the data from the University of Michigan, the covariance matrix parameters were estimated at approximately $\sigma^2 = 0.757$ (variance parameter) and $\rho = 0.936$ (correlation parameter). To be conservative, the power calculations for the primary analysis were performed with parameter setting of $\sigma^2 = 0.810$ (variance parameter) and $\rho = 0.925$ (correlation parameter).

The power calculations assume a correction for imperfect compliance proposed by Lachin and Foulkes to allow for 2\% noncompliance for each of the treatment arms.\textsuperscript{47} Thus, the sample size of 130 subjects per arm would be reduced to an adjusted sample size of $130 \times (1 - 0.02 - 0.02)^2 = 119.8$ or 120 subjects per arm.

Under the assumed Type I error rate of 0.05, with a correlation parameter of 0.925 and standard deviation of 0.90, the difference of 0.15 L (or 0.0025 L/week) shown in Table 6 would have power of 93\%.
Table 6: Hypothetical Values of Mean FVC (L) Change from Baseline

<table>
<thead>
<tr>
<th></th>
<th>Week 15</th>
<th>Week 30</th>
<th>Week 45</th>
<th>Week 60</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAC</td>
<td>0.0125</td>
<td>0.0250</td>
<td>0.0375</td>
<td>0.0500</td>
</tr>
<tr>
<td>Placebo</td>
<td>0.0500</td>
<td>0.1000</td>
<td>0.1500</td>
<td>0.2000</td>
</tr>
<tr>
<td>Difference</td>
<td>0.0375</td>
<td>0.0750</td>
<td>0.1125</td>
<td>0.1500</td>
</tr>
</tbody>
</table>

Abbreviations: FVC, forced vital capacity; PL, placebo

9.7.2. Power Analysis for Secondary Endpoints

Power calculations for secondary endpoint measurements are shown in Table 7. Standard deviations are based on unpublished data provided by the University of Michigan. The calculations are based on a 2-sample t-test with Type I error rate set at 0.05. These calculations are likely to be conservative because the statistical approach, described in section 9.5, for analyzing these endpoints will incorporate incomplete observations as well as intermediate data points.

Table 7: Detectable Differences in Treatment Means for Selected Endpoint Measurements

<table>
<thead>
<tr>
<th>Secondary Endpoints</th>
<th>Std Dev of the Baseline Score</th>
<th>Detectable Difference for 80% Power</th>
<th>Std Dev of the Change Score</th>
<th>Difference Detectable for 80% Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLCO%pred</td>
<td>16.6</td>
<td>5.8</td>
<td>9.1</td>
<td>3.2</td>
</tr>
<tr>
<td>6MWT Area Under the Desaturation Curve</td>
<td>21.9</td>
<td>7.6</td>
<td>17.5</td>
<td>6.1</td>
</tr>
<tr>
<td>6MWT Distance to Desaturation</td>
<td>22.4</td>
<td>7.8</td>
<td>31.5</td>
<td>11.0</td>
</tr>
<tr>
<td>6MWT Minutes Walked</td>
<td>2.10</td>
<td>0.73</td>
<td>2.05</td>
<td>0.71</td>
</tr>
</tbody>
</table>

Abbreviations: Std Dev, standard deviation; DLCO%pred, diffusing capacity of the lung for carbon monoxide percent predicted; 6MWT, 6-minute walk test
10. Study Administration

10.1. Cooperative Agreement Mechanism

The administrative and funding mechanism used to undertake this project is a “cooperative agreement” (U01), which is an assistance mechanism. Under the cooperative agreement, the NHLBI assists, supports, and/or stimulates the project and is substantially involved with investigators in conducting the study by facilitating performance of the effort in a “partner” role. The NHLBI project scientist serves on the IPFnet Steering Group, and he or another NHLBI scientist may serve on other project committees when appropriate. At the same time, however, NHLBI does not assume a dominant role, direction, or prime responsibility for this research program.

As described below, governance of the project is conducted through the IPFnet Steering Group. Principal investigators have lead responsibilities in all aspects of their trials and the project, including any modification of trial designs, conduct of the trials, quality control, data analysis and interpretation, preparation of publications, and collaboration with other investigators, unless otherwise provided for by the IPFnet Steering Group.

PIs retain custody of and have primary rights to their center-specific and collaborative data, subject to government rights-of-access consistent with current Health & Human Services (HHS), Public Health Service (PHS), and National Institutes of Health policies. The protocols and governance policies call for the continual submission of data centrally to the IPFnet DCC for the collaborative database, which at a minimum will contain the key variables selected by the IPFnet Steering Group for standardization across all clinical centers; the submission of copies of the collaborative datasets to each PI upon completion of the project; procedures for data analysis, reporting and publication; and procedures to protect and ensure the privacy of medical and genetic data and records of individuals. The NHLBI project scientist, on behalf of the NHLBI, will have the same access, privileges, and responsibilities regarding the collaborative data as the other members of the Steering Group.
PIs are also encouraged to publish and to publicly release and disseminate results, data, and other products of the project, concordant with the project protocols and governance and the approved plan for making data and materials available to the scientific community and to the NHLBI. However, during the 3 years after the ending date of NHLBI project support, unpublished data, unpublished results, data sets not previously released, and other study materials or products are to be made available to any third party only with the approval of the IPFnet Steering Group.

Upon completion of the project, PIs are expected to put their intervention materials and procedure manuals into the public domain and/or make them available to other investigators according to the approved plan for making data and materials available to the scientific community and the NHLBI for the conduct of research, at no charge other than the costs of reproduction and distribution.

The NHLBI reserves the right to terminate or curtail the project (or an individual award) in the event of (a) failure to develop or implement mutually agreeable collaborative measurement, subject eligibility, and data management sections of the protocols; (b) substantial shortfall in subject recruitment, follow-up, data reporting, or quality control or other major breach of protocol; (c) substantive changes in the agreed-upon protocols with which NHLBI cannot concur; (d) reaching a major project outcome, with persuasive statistical significance, substantially before schedule; or (e) human subject ethical issues that may dictate a premature termination.

Any disagreement that may arise in scientific/programmatic matters (within the scope of the award) between award recipients and the NHLBI may be brought to arbitration. An arbitration panel will be composed of 3 members—1 selected by the IPFnet Steering Group (with the NHLBI member not voting) or by the individual PI in the event of an individual disagreement, a second selected by NHLBI, and the third selected by the other 2 members. This special arbitration procedure in no way affects the PI’s right to appeal an adverse action that is otherwise appealable in accordance with the PHS regulations at 42 CFR part 50, Subpart D and HHS
regulation at 45 CFR part 16 or the rights of the NHLBI under applicable statutes, regulations, and terms of the award.

10.2. IPFnet Steering Group

The IPFnet Steering Group is the main governing body of the project. It is composed of the PIs of the clinical centers, the PI of the DCC, and the NHLBI project scientist. The clinical centers, the IPFnet DCC, and the NHLBI each have 1 vote on the IPFnet Steering Group. All decisions are determined by majority vote.

All major scientific decisions are determined by the IPFnet Steering Group. It assumes overall responsibility for the design and conduct of the trial. It appoints (and disbands) committees and subcommittees as the need arises; designs, approves, and implements the study protocols; oversees the development of the MOOP; monitors subject recruitment and treatment delivery; evaluates data collection and management; oversees quality assurance procedures; and implements changes and enhancements to the study as required. It also has primary responsibility for facilitating the conduct of the trials and reporting the project’s results.

10.3. Data and Safety Monitoring Board

The NHLBI will establish a DSMB in accordance with established policies (see http://www.nhlbi.nih.gov/funding/policies/dsmb_inst.htm) to ensure data quality and subject safety and to provide independent advice to the NHLBI regarding progress and the appropriateness of study continuation.

10.4. Recommendations on Interim Monitoring of Efficacy, Safety, and Futility

First and foremost the role of the DSMB will be to review subject safety and trial conduct at periodic points during the study. The DSMB may require analyses of the primary endpoint results for comparing the benefit and risks of treatment strategies. The benefit of collecting additional data on key secondary endpoints, with extended follow-up, and establishing a robust
evidence base for determining a standard of care will need to be carefully considered before early termination of one or more treatment arms. After careful consideration, the IPFnet Steering Group recommends conservative thresholds for the early examinations of the safety and efficacy data.

The DSMB will be expected to meet approximately every 6 months until trial completion to review safety and toxicity data. The DSMB may recommend stopping the study based on these reviews. Because the DSMB could stop the trial for safety concerns as well as for a large efficacy benefit, there could be multiple opportunities to reject the null hypothesis (no difference in event rates between the PL and NAC groups). A Bonferroni approximation will be applied during the one planned interim analysis for efficacy.

Before locking the database, a statistical analysis plan (SAP) will be developed to provide complete details on the statistical analysis. The SAP will include the specifics for how and when the DSMB will be notified for AEs. The IPFnet DCC will deliver to the DSMB all FDA-defined AEs at 3-month intervals. The IPFnet DCC will prepare narrative SAE reports in real time for DSMB review including recommendations and analysis of similar events for each SAE submitted to the FDA.
11. Investigator and Sponsor Obligations

11.1. Monitoring

All monitoring activities for U.S. clinical centers will be performed in accordance with DCRI standard operating procedures. Information regarding the types of visits will be outlined in the PANTHER-IPF MOOP.

11.2. Cost and Payment

There will be no cost to subjects enrolled in this trial. Study-related procedures will be paid for by the IPFnet.

Subjects may be eligible for reimbursement for travel to the clinical center. Details of payment will be explained to each subject during the consent process.

11.3. Confidentiality and Health Insurance Portability and Accountability Act Considerations

Subject confidentiality will be protected throughout the study. All subject data will be kept strictly confidential, and no subject-identifying information will be released to anyone outside the project. Confidentiality will be assured through several mechanisms. First, each subject will be assigned an anonymous study ID, which will then be used on all study forms. Second, any study forms, blood samples, and paper records that contain subject information (eg, address lists, phone lists) will be kept at the clinical centers in secured, locked areas, coded by number. Once blood is collected, there will be no subject identifiers placed on blood samples—only the study ID number and the date of sample collection. Third, access to all subject data and information, including laboratory specimens, will be restricted to authorized personnel. In the case of computerized data, this restricted access will be assured through user logon IDs and password protection.
At the IPFnet DCC, only authorized personnel will have access to the data files containing study data. Security will be assured through user logon IDs, passwords, and appropriate access privileges. All study subjects will be identified only by their IPFnet ID numbers, and no personal identifying information, such as name, address, or Social Security number, will be entered into the IPFnet DCC database. Any subject-specific data reported to the IPFnet Steering Group will be identified only by the IPFnet ID number.

Finally, subjects will not be identified by name in any reports or publications, nor will the data be presented in such a way that the identity of individual subjects can be inferred. Analysis files created for further study by the scientific community will have no subject identifiers. These data files will be created in accordance with the Ancillary Studies and Publication Policy of the IPFnet.

11.4. Informed Consent Procedures

All IPFnet subjects will provide written informed consent using procedures reviewed and approved by each clinical center’s IRB. Informed consent will be undertaken by study personnel in-person with the subject. The subject has the option of declining further participation in the study at that point. No further study procedures will be conducted until the signed documents have been provided to the IPFnet clinical center.

11.5. Institutional Review Boards

Before initiating this study, the protocol, clinical center-specific informed consent forms, Health Insurance Portability and Accountability Act (HIPAA) forms, recruitment materials, and other relevant information will be reviewed by a properly constituted IRB at each participating clinical center. A copy of the signed and dated IRB approval at each clinical center will be retrieved prior to or during the site initiation visit and archived at the IPFnet DCC. Any amendments to the protocol, other than simple administrative and typographical changes, must be approved by each IRB before they are implemented. The clinical centers will seek annual renewals of their IRB approvals in accordance with local procedures.
12. Investigator Agreement

I have read the foregoing protocol, PANTHER-IPF, and agree that it contains all necessary details for carrying out this study. I will conduct the study as outlined herein and will complete the study within the time designated.

I will provide copies of the protocol and all pertinent information to all individuals responsible to me who assist in the conduct of this study. I will discuss this material with them to ensure they are fully informed regarding the drug and the conduct of the study.

I will fulfill all responsibilities for submitting pertinent information to the local IRB, if applicable, that is responsible for this study.

I further agree that NHLBI and/or DCRI will have access to any source documents from which eCRF information may have been generated.

__________________________________________  ________________
Signature of Principal Investigator Date

__________________________________________
Name of Principal Investigator (printed or typed)

Protocol version date: May 19, 2009
Protocol Amendment 1 version date: May 28, 2010
Protocol Amendment 2 version date: December 6, 2011
13. References